Antimicrobial Resistance Market Industry is projected to reach US$ 9.5 Billion by 2032 | AMR

According to the report published by Allied Market Research, the global antimicrobial resistance market was valued at $4.6 billion in 2022, and is projected to reach $9.5 billion by 2032, registering a CAGR of 7.6% from 2023 to 2032. The report offers an in-depth analysis of the market size, emerging and current trends, future estimations, and key players.

Antimicrobial resistance, often abbreviated as AMR, is the term used to describe the ability of microorganisms to resist the effects of various antimicrobial substances. Microbial species including fungi, bacteria, viruses, and others can develop this resistance over time. These microorganisms can become resistant to one or more drugs, leading to situations where they are resistant to multiple drugs, a condition known as multi-drug resistance or sometimes colloquially referred to as a “superbug,” particularly when they are resistant to almost all available antibiotics, which is called pan-resistant bacteria.

Request Sample Copy of Report: 

https://www.alliedmarketresearch.com/request-sample/180698

Impact of COVID-19 on Antimicrobial Resistance Market:

Increased Antimicrobial Use:

• COVID-19 treatment: Despite limited evidence of effectiveness, antimicrobials were widely used in COVID-19 patients for potential secondary bacterial infections. This off-label use, particularly with broad-spectrum antibiotics, contributed to increased selection pressure for resistant bacteria.
• Fear of secondary infections: Patients and healthcare professionals, due to anxieties surrounding COVID-19 complications, often demanded or prescribed unnecessary antibiotics, further driving overuse.

Disruptions in AMR Control Measures:

• Focus shift: Resources and attention shifted towards managing the pandemic, leading to disruptions in existing AMR control programs and surveillance activities. This hampered efforts to track resistant bacteria and implement preventative measures.
• Supply chain disruptions: Shortages of certain antimicrobials and diagnostic tools due to global supply chain disruptions hindered proper diagnosis and treatment of bacterial infections, potentially leading to inappropriate antimicrobial use.

Positive Developments:

• Increased awareness: The pandemic highlighted the critical threat of AMR to global health, leading to increased public awareness and advocacy for effective AMR control measures.
• Research and development: Investments in research on novel antimicrobials and alternative therapies for combating resistant bacteria have increased, driven by the urgency of addressing AMR.
• Focus on antimicrobial stewardship: Recognition of the dangers of inappropriate antimicrobial use has spurred renewed efforts to promote antibiotic stewardship programs and optimize antimicrobial prescribing practices.

Key findings of the study

• On the basis of drug class, combination therapies segment dominated the market in 2022.
• On the basis of indication, complicated urinary tract infections (cUTI) segment dominated the antimicrobial resistance industryin 2022.
• On the basis of pathogen, E. coli segment dominated the market in 2022.
• On the basis of mechanism of action, cell wall synthesis inhibitors segment dominated the market in 2022.
• On the basis of region, North America dominated the market in 2022. However, Asia-Pacific is the fastest-growing segment during the forecast period.

For Procurement Information- 

https://www.alliedmarketresearch.com/purchase-enquiry/180698

Key Market Segments:

Leading Market Players: – 

• Alkem Laboratories Ltd.
• Pfizer Inc.
• Acurx Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd
• Cumberland Pharmaceuticals
• Wockhardt Limited.
• Paratek Pharmaceuticals Inc
• Nabriva Therapeutics Plc
• Innoviva, Inc
• Merck And Co., Inc.

Want to Explore More, Connect to our Analyst- 

https://www.alliedmarketresearch.com/connect-to-analyst/180698

North America to maintain its dominance by 2032 

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for nearly three-fifths of the global antimicrobial resistance market revenue. North America is witnessing notable growth trends, owing to its well-developed healthcare industry and easy availability of advanced medical solutions.

On the other hand, Asia-Pacific region is anticipated to be the fastest growing region estimated to display the fastest CAGR of 8.4% from 2023 to 2032, which is attributed to the large population base in countries such as China and India, rising healthcare expenditure, huge burden of infectious diseases and developing healthcare infrastructure.

Other Trending Reports in Life Science Domain- 

Animal Model Market: https://www.alliedmarketresearch.com/animal-model-market-A07946

Sperm Bank Market: https://www.alliedmarketresearch.com/sperm-bank-market-A10372

U.S. Home Medical Equipment Market: https://www.alliedmarketresearch.com/us-home-medical-equipment-market-A11059

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact Us:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com